Home › Funds › Elmind Capital, LP › CGEM
Elmind Capital, LP position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
Elmind Capital, LP reported holding 690,000 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$12.6M, representing 3.16% of its reported portfolio and ranking #13 among its reported holdings. Elmind Capital, LP has disclosed CGEM holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's CGEM position evolved
Elmind Capital, LP first disclosed a stake in CGEM in Q4 2025 at 310,000 shares (US$3.2M). The position peaked in Q2 2026 at 690,000 shares, worth US$12.6M. Across 3 filings, Elmind Capital, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 690,000 shares valued at US$12.6M — an increase of 160,000 shares quarter over quarter.. Notable position changes include a 71% increase in Q1 2026 (shares rose 28% over the following quarter), a 30% increase in Q2 2026 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 310.00K | $3.21M | New |
| Q1 2026 | 530.00K | $7.53M | Add |
| Q2 2026 | 690.00K | $12.56M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.73M sh · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- BVF INC/IL 5.75M sh · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.89M sh · $34.48M · Q2 2026
- Blue Owl Capital Holdings LP 1.54M sh · $28.04M · Q2 2026
- Venrock Adviser, LLC 1.38M sh · $25.13M · Q2 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K sh · $15.95M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K sh · $10.84M · Q2 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held CGEM?
Elmind Capital, LP has disclosed CGEM holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in CGEM?
As of Q2 2026, Elmind Capital, LP holds 690.00K shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $12.56M, representing 3.16% of its reported portfolio and ranking #13.
Has Elmind Capital, LP been buying or selling CGEM?
In the latest 13F filing (Q2 2026), Elmind Capital, LP increased its position in CGEM. The position peaked in Q2 2026 at 690.00K shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.